|
20.12.2024 17:07:24
|
Merit Medical's Wrapsody Cell-Impermeable Endoprosthesis Receives FDA Pre-market Approval
(RTTNews) - Merit Medical Systems, Inc. (MMSI), Friday announced that its Wrapsody Cell-Impermeable Endoprosthesis has secured premarket approval from the Food and Drug Administration, enabling its commercialization in the U.S. in 2025.
The device is designed to extend long-term vessel patency in dialysis patients, who rely on a vascular access site created in the arm called an arteriovenous or AV fistula or an AV graft.
As per the Wrapsody WAVE pivotal trial data, AV graft patients receiving treatment with the Wrapsody device for dialysis outflow lesions achieved a target lesion primary patency of 89.8 percent and 82.0 percent, respectively, at six months, the company stated.
Currently, Merit Medical's stock is trading at $98.40, up 2.22 percent on the Nasdaq.
Nachrichten zu Merit Medical Systems Inc.
Analysen zu Merit Medical Systems Inc.
Im BX Morningcall werden folgende Aktien analysiert und erklärt:
✅ LPL Finance
✅ Blackstone
✅ Ares Management
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| Merit Medical Systems Inc. | 102.86 | -1.88% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
SMI geht fester aus dem Handel -- DAX schliess nach neuem Rekord freundlich -- Börsen in Fernost letztlich mehrheitlich im PlusDer heimische Aktienmarkt zeigte sich am Donnerstag im Plus. Der deutsche Aktienmarkt notierte höher. Die US-Börsen schlagen unterschiedliche Richtungen ein. Asiens Börsen verbuchten am Donnerstag überwiegend Gewinne.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |